Has Moderna Made a Bear Market Blunder?
In the past 12 months, shares of healthcare company Moderna (NASDAQ: MRNA) have fallen by more than 55% (the S&P 500 is down just 4% over that stretch). Although the company has generated billions from its COVID-19 vaccine, investors are getting more concerned about what the future looks like for the company beyond just COVID. Moderna has been sitting on billions in cash that could go a long way in investing in its business or even acquiring another company to expand its reach.
